Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.
We aimed to study the efficacy and safety of metronomic capecitabine in pretreated elderly patients with advanced gastric cancer. Eligible patients with advanced gastric cancer were treated with capecitabine at a fixed dose 1,000 mg daily (days 1-28 continuously, every 5 weeks) until disease progression or significant toxicity. Tumor response was assessed every 10 weeks by computed tomography scan using Response Evaluation Criteria in solid tumors. In total, 45 patients were enrolled, of whom 43 were evaluated for efficacy and 45 for safety. A median of 3 cycles (range 1-12) were administered. Metronomic chemotherapy had a disease control rate (DCR) at 8 weeks of 51.1% (95% CI 25.7-67.8), and the objective response rate was 20.9% (95% CI 13.1-38.5, 9 of 43 assessable patients). The median time-to-progression and median overall survival were 3.6 months (95% CI: 3.2-4.0 months) and 7.6 months (95% CI 7.0-8.2 months), respectively. Grade II neutropenia and thrombocytopenia were observed in 13.3 and 2.2% of patients, respectively. Grade II/III nonhematological toxicities included diarrhea (4.4%), stomatitis (13.4%), and hand-foot syndrome (15.5%). No grade IV toxicity, neutropenic fever or treatment-related deaths occurred. Metronomic capecitabine was effective and well tolerated as palliative treatment in elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.
Department of Medical Oncology, Cancer Hospital, Minhang Branch, Fudan University, 106 Ruili Road, Minhang District, Shanghai 200240, China. hlshli@yahoo.com.cn
ShengLi
S
He
Jie
J
Shen
Liang
L
Hong
LuMing
L
Niu
DaoYong
D
Niu
D059250:Administration, Metronomic; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D010166:Palliative Care / Q000379:methods*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
Ann Oncol. 2004 Nov;15(11):1585-95
15520058
Tumori. 2009 Nov-Dec;95(6):843-5
20210257
Onkologie. 2007 Dec;30(12):606-8
18063872
J Clin Oncol. 2006 Jun 20;24(18):2903-9
16782930
J Chemother. 2007 Aug;19(4):359-75
17855179
World J Gastroenterol. 2004 Mar 15;10(6):804-8
15040021
Pharmacotherapy. 2009 Mar;29(3):318-30
19249950
Oncology. 2003;64(3):232-6
12697963
Ann Oncol. 2004 Sep;15(9):1344-7
15319239
J Clin Oncol. 2007 May 10;25(14):1832-43
17488981
Br J Cancer. 2008 May 20;98(10):1619-29
18443598
Gastrointest Cancer Res. 2009 Jul;3(4):134-40
19742139
Clin Transl Oncol. 2008 Sep;10(9):583-6
18796376
Br J Cancer. 2008 Aug 19;99(4):584-90
18665164
Cancer Lett. 2008 Aug 18;267(1):26-36
18420342
Jpn J Clin Oncol. 2009 Jan;39(1):43-8
18997184
Cancer Treat Rep. 1987 Nov;71(11):1079-85
3315196
Anticancer Drugs. 2008 Mar;19(3):303-7
18510177
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064
20238327
Chemotherapy. 2010;56(2):166-70
20407245
Cancer Invest. 2004;22(5):713-7
15581052
Cancer Chemother Pharmacol. 2009 Jun;64(1):189-93
19151974
Eur J Cancer. 1998 Jul;34(8):1274-81
9849491
Neuro Oncol. 2007 Jul;9(3):354-63
17452651
Ann Oncol. 2002 Apr;13(4):566-75
12056707
Onkologie. 2007 Dec;30(12):629-35
18063875
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22
14561896
Nat Rev Clin Oncol. 2010 Aug;7(8):455-65
20531380
Am J Clin Oncol. 2004 Oct;27(5):477-80
15596914
J Clin Oncol. 2008 Oct 20;26(30):4899-905
18794539
J Hepatol. 2010 Jul;53(1):126-31
20416968
Eur J Cancer. 2006 May;42(7):827-34
16466913
J Egypt Natl Canc Inst. 2008 Jun;20(2):134-40
20029469
Anticancer Drugs. 2008 Jan;19(1):91-6
18043134
Br J Cancer. 2010 Apr 13;102(8):1207-12
20354522
Oncol Res. 2010;18(11-12):601-5
20939436
J Clin Oncol. 2004 Nov 15;22(22):4626-31
15542812
Lancet Oncol. 2008 Mar;9(3):215-21
18282805
J Clin Oncol. 2006 Nov 1;24(31):4991-7
17075117
Eur J Cancer Care (Engl). 2007 May;16(3):258-62
17508946
Br J Cancer. 2004 Mar 22;90(6):1190-7
15026800